XML 48 R38.htm IDEA: XBRL DOCUMENT v3.25.1
Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Bayer (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Disaggregation of Revenue [Line Items]    
Revenues $ 3,028.7 $ 3,145.0
Bayer | Rest Of World | Collaboration revenue | Regeneron's share of profits    
Disaggregation of Revenue [Line Items]    
Revenues 317.3 333.9
Bayer | Rest Of World | Collaboration revenue | Reimbursement for manufacturing of commercial supplies    
Disaggregation of Revenue [Line Items]    
Revenues 26.6 22.1
Bayer | Rest Of World | (R&D expense) | Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses    
Disaggregation of Revenue [Line Items]    
Revenues $ (9.4) $ (8.7)